Checkpoint Inhibitor denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Your Checkpoint Inhibitor — Quantity Limits

Cigna applies quantity limits to checkpoint inhibitors to align reimbursement with the dosing regimens specified in the FDA-approved labeling. A quantity-limit denial typically arises when the prescribed dose, frequency, or number of cycles exceeds the default limit coded into Cigna's formulary — even when the prescriber has clinical justification for the requested amount. This denial is not a finding that the drug is medically unnecessary; it is a formulary management tool, and it is regularly overturned on appeal.

## Federal Appeal Framework

• Internal appeal: File within 180 days. Urgent oncology cases qualify for expedited review (72-hour turnaround required by federal regulation).
• Exception/override request: Simultaneously file a quantity-limit exception with the PA team, which may resolve the issue faster than the full appeal track.
• ACA §2719 external review: After the internal process, request independent external review within the ~4-month window from the original denial date.
• ERISA §503 (employer-sponsored plans): You have the right to the full clinical criteria and formulary policy applied to the denial.

## Documentation to Gather

1. Prescribing label dosing information: Confirm the requested quantity is consistent with the FDA-approved dosing schedule for the specific checkpoint inhibitor in your indication. Obtain the current label from the FDA or the manufacturer. 2. Oncologist's letter of medical necessity: Should explain why the prescribed dosing schedule — including frequency and cycle length — is clinically appropriate for this patient's body surface area, organ function, toxicity history, and disease course. 3. Cigna's quantity-limit policy: Request the exact limit that triggered the denial and the supporting rationale. 4. Administration records: If already receiving treatment, provide infusion records showing doses administered, dates, and tolerability. 5. Response assessment: Imaging or lab data documenting tumor response or stable disease to support continuation at the prescribed schedule.

## Criteria-Mapping Structure

Obtain the FDA-approved prescribing label for the specific checkpoint inhibitor — it will state the approved dosing regimen and any weight-based or BSA-based adjustments. Obtain Cigna's quantity-limit policy for this drug. Map each element: approved dose per administration, approved interval, approved number of cycles (where stated), and any provisions for dose modification. Then document precisely how the prescription aligns with or is clinically justified relative to that framework.

If the prescriber has modified the standard schedule based on the patient's clinical status (e.g., extended intervals for toxicity management), the oncologist should explain the clinical rationale explicitly — dose modifications for tolerability are a recognized standard of care and should be covered within an approved indication.